The Europe Mycoplasma Testing Market would witness market growth of 11.1% CAGR during the forecast period (2023-2030).
Academic research institutions and laboratories conducting cell culture studies have become increasingly aware of the impact of mycoplasma contamination on experimental outcomes. As a result, researchers are integrating this testing into their routine laboratory practices to maintain the reliability and reproducibility of their studies. The adoption is fueled by a proactive approach to ensuring the validity of research results and preventing mycoplasma's spread in shared laboratory environments.
This testing is extensively used in cell culture laboratories for routine quality control. Contaminated cell cultures can lead to unreliable experimental results, compromised data integrity, and potential cross-contamination in shared laboratory spaces. Regular testing ensures the purity of cell lines, contributing to the reproducibility and accuracy of research outcomes in fields such as molecular biology, cancer research, and virology.
Germany has a robust biopharmaceutical industry, with numerous companies engaged in developing and producing biologics, monoclonal antibodies, and other advanced therapies. The presence of biomanufacturing facilities in Germany that produce vaccines, cell and gene therapies, and recombinant proteins contributes to the demand for this testing. Germany is home to leading research institutions and universities engaged in cell culture research. As the adoption of cell cultures increases in various research applications, this testing becomes crucial to maintaining the integrity of experiments and ensuring reliable research outcomes in Germany. The pharmaceutical R&D sector in Germany is a driving force in drug discovery and development. Hence, all these factors will uplift the regional market’s expansion in the coming years.
The Germany market dominated the Europe Mycoplasma Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $116.8 million by 2030. The UK market is exhibiting a CAGR of 10.1% during (2023 - 2030). Additionally, The France market would experience a CAGR of 11.9% during (2023 - 2030).
Free Valuable Insights: The Global Mycoplasma Testing Market will Hit $1.9 Billion by 2030, at a CAGR of 11.5%
Based on Product & Service, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into PCR, ELISA, Microbial Culture Techniques, and Enzymatic Methods. Based on Application, the market is segmented into Cell Line Testing, Virus Testing, End of Production Cells Testing, and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Cell Banks, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
By Product & Service
By Technology
By Application
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
